Skip to main content

Direxion Daily S&P Biotech Bear 3x Shares (LABD)

NYSEARCA: LABD · IEX Real-Time Price · USD
21.85 -0.05 (-0.23%)
Oct 22, 2021 4:00 PM EDT - Market closed
Expense Ratio1.07%
PE Ration/a
Shares Out2.07M
Dividend (ttm)n/a
Dividend Yieldn/a
Ex-Dividend DateMar 24, 2020
1-Year Return
Previous Close21.90
Day's Range21.82 - 23.00
52-Week Low12.30
52-Week High58.06
Inception DateMay 28, 2015

About LABD

The investment seeks daily investment results, before fees and expenses, of 300% of the inverse of the daily performance of the S&P Biotechnology Select Industry Index. The fund, under normal circumstances, invests in swap agreements, futures contracts, short positions or other financial instruments that, in combination, provide inverse (opposite) or short leveraged exposure to the index equal to at least 80% of the fund's net assets (plus borrowing for investment purposes). The index is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standards (GICS). The fund is non-diversified.

Asset ClassPortfolio-Multi Asset
IssuerDirexion Investments
Stock ExchangeNYSEARCA
Ticker SymbolLABD
Index TrackedS&P Biotechnology Select Industry Index


Ex-DividendAmountPay Date
Mar 24, 2020$0.9952Mar 31, 2020
Dec 23, 2019$0.278Dec 31, 2019
Sep 24, 2019$1.1708Oct 1, 2019
Jun 25, 2019$1.7478Jul 2, 2019
Mar 19, 2019$1.1286Mar 26, 2019
Dec 27, 2018$3.8268Jan 4, 2019
Full Dividend History


This Bearish Biotech ETF Is up 16% in the Past Month

The biotech sector was one of the darlings amid the vaccine rally in 2020, but there's since been some bearishness, which is benefiting the Direxion Daily S&P Biotech Bear 3X Shares (LABD). LABD climbed...

1 week ago - ETF Trends

Rising Yields Rattles Market: Inverse ETFs in Vogue

Wall Street resumed its quarter-end decline in the face of rising yields. This has resulted in a spike in inverse or inverse leveraged ETFs.

Other symbols:SOXSTECSWEBS
2 weeks ago - Zacks Investment Research

6 Top-Performing Leveraged/Inverse ETFs of September

September proved the historical trends to be true as Wall Street logged in the worst month of this year.

3 weeks ago - Zacks Investment Research

5 Inverse ETFs Jump Most on Market Sell-Off

We have highlighted the five best-leveraged inverse ETFs that piled up handsome gains on the broad sell-off.

Other symbols:SOXSSQQQWEBS
3 weeks ago - Zacks Investment Research

6 Inverse ETFs Gain on Broad Market Sell-Off

The broad market sell-off has resulted in a spike for inverse or inverse leveraged ETFs. These products either create a short position or a leveraged short position in the underlying index.

1 month ago - Zacks Investment Research

September Lull Starts: Inverse ETFs Won Last Week

Wall Street witnessed a bloodbath last week, resulting in a solid run-up in inverse ETFs.

1 month ago - Zacks Investment Research

5 Top-Performing Leveraged/Inverse ETFs of July

While earnings optimism and a rebounding economy pushed the three major indices to new highs in July, concerns about the spread of the Delta variant of COVID-19 made investors jittery.

Other symbols:CUREDRNUTSL
2 months ago - Zacks Investment Research

7 Inverse ETFs Riding High on Nasdaq Sell-Off

We have highlighted seven inverse ETFs that benefited the most from the Nasdaq sell-off.

5 months ago - Zacks Investment Research

5 Inverse/Leveraged ETF Areas of Last Week

The last week was extremely upbeat for Wall Street with the S&P 500 and the Dow Jones at record highs.

Other symbols:DRIPTECLWANT
6 months ago - Zacks Investment Research

7 Best Leveraged/Inverse ETFs Up 20% Plus in March

Amid the bull and bear tug-of-war, the demand for leveraged and inverse-leveraged ETFs has increased.

6 months ago - Zacks Investment Research

Top Inverse/Leveraged ETFs of Last Week

Last week was mixed for Wall Street. Tax hike fears, rising COVID-19 cases and still-existing rising rate worries led to the volatility.

Other symbols:BZQJDSTNAIL
6 months ago - Zacks Investment Research

Biotech Rose with the Virus. Now It's Falling Behind

The S&P 500 Biotech index rose as much as 25% last year after falling as low as 8% during the apex of last year's sell-offs. Now, downward pressure is helping leveraged inverse funds like the Direxion D...

7 months ago - ETF Trends

Top 4 Inverse/Leveraged ETF Areas of Last Week

The first week of March was mixed for Wall Street. The energy sector has been the key winner.

7 months ago - Zacks Investment Research

Top 5 Leveraged ETFs of Last Week

Wall Street crashed last week with the S&P 500, the Dow Jones, the Nasdaq Composite and the Russell 2000 losing about 2.5%, 1.8%, 4.9% and 2.4%, respectively.

Other symbols:BZQEDZYANG
7 months ago - Zacks Investment Research

Winning Leveraged ETFs of the Final Week of 2020

Wall Street saw a mixed performance last week probably because of rising COVID-19 cases globally while a stimulus deal cheered up the market.

9 months ago - Zacks Investment Research

Post-Vaccine Distribution, Mergers Will Dominate Biotech Industry ETFs

The COVID-19 pandemic put biotech in the spotlight as companies around the globe worked feverishly to create a vaccine. Once a tried-and-true vaccine is developed and subsequently incorporated as standa...

11 months ago - ETF Trends

3 Bearish ETFs To Profit Bullish Counterparts With Elevated Short Interest

It's not just stocks that are made for shorting. Plenty of traders tap exchange-traded funds on the bearish side of things and do so for a variety of reasons.

Other symbols:EDZ
1 year ago - Benzinga

Consider These 2 Leveraged Biotech ETFs to Ride The M&A Trend

The biotech and healthcare space has been on fire lately. The healthcare space is witnessing a Mergers and Acquisitions wave recently that has achieved an impressive $342 billion in new deal activity so...

Other symbols:LABU
1 year ago - ETF Trends

6 Best Leveraged Inverse ETFs of Past Week

We have highlighted six leveraged inverse ETFs that are up more than 15% over the past week.

Other symbols:DRIPDUGERY
2 years ago - Zacks Investment Research

These Are The Leveraged ETFs At Play When Trade War Worries Strike

The U.S.-China trade war is more than 18 months old. And in that time the conflict has taken a toll on stocks across the world and put company executives and market watchers alike on edge.

2 years ago - Benzinga